脑梗塞患者t-PA、PAI检测的临床意义  

Clinical Study on Plasma t-PA and PAI in Patients with Cerbral Infarction

作　　者：陈婷[1] 黎源[1] 魏辉平[1] 涂艳平 魏群[1] 曾海涛[1] 

机构地区：[1]江西省人民医院,南昌330006

出　　处：《现代诊断与治疗》1995年第2期83-84,共2页Modern Diagnosis and Treatment

摘　　要：采用发色底物显色法检测34例脑梗塞患者血浆t-PA、PAI活性,结果t-PA 1.03±0.23 IU,PAI 9.05±1.12AU,与健康人比较有显著性差异(P<0.01).提示患者纤溶活性降低.本组呈现t-PA愈低,PAI愈高,患者病情愈重.复发机会愈多的趋势.我们认为t-PA及PAI活性的检测对脑梗塞及血栓前状态的诊断、治疗有一定的临床意义及参考价值.对使用纤溶剂出血等副作用的监测和预防有重要的临床意义.We determinated the contents of tissue type plasminogen activator (t-PA) and plasminogen inhibitor (PAD in the plasma of 34 cases with cere-bral infarction, The results showed that Both were 1. 03±0. 23IU/ml, and 9. 05±1. 12AU/ml separate-ly. There was obvlous differences in contrast with healthy cases (P<0. 01). It showed that the activity of fibrinolytic system in patients with cerebral infarc-tion was reduced. The results revealed that the more lower plasma t-PA and more higher plasma PAI was separately, the more serious of the illness state was. We considered that the determination of plasma t-PA, PAI has an important referable significance in clinical diagnosis and treatment of cerebral infarction and pre-embolism status and in the survillance and prevention of the side-effect such as hemorrhage etc when fibrolytic therapy was used.

关 键 词：脑梗塞 组织型 纤溶酶原活化物 纤溶酶原抑制物 

分 类 号：R743.33[医药卫生—神经病学与精神病学]